86 related articles for article (PubMed ID: 15632367)
1. Lymphatic regeneration: new insights from VEGFR-3 blockade.
Aoki Y; Tosato G
J Natl Cancer Inst; 2005 Jan; 97(1):2-3. PubMed ID: 15632367
[No Abstract] [Full Text] [Related]
2. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody.
Pytowski B; Goldman J; Persaud K; Wu Y; Witte L; Hicklin DJ; Skobe M; Boardman KC; Swartz MA
J Natl Cancer Inst; 2005 Jan; 97(1):14-21. PubMed ID: 15632376
[TBL] [Abstract][Full Text] [Related]
3. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
[TBL] [Abstract][Full Text] [Related]
5. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
Tvorogov D; Anisimov A; Zheng W; Leppänen VM; Tammela T; Laurinavicius S; Holnthoner W; Heloterä H; Holopainen T; Jeltsch M; Kalkkinen N; Lankinen H; Ojala PM; Alitalo K
Cancer Cell; 2010 Dec; 18(6):630-40. PubMed ID: 21130043
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
[TBL] [Abstract][Full Text] [Related]
7. Molecular control of lymphatic metastasis.
Achen MG; Stacker SA
Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
[TBL] [Abstract][Full Text] [Related]
8. Suppression of lymphangiogenesis induced by Flt-4 antibody in gastric low-grade mucosa-associated lymphoid tissue lymphoma by Helicobacter heilmannii infection.
Nakamura M; Matsui H; Takahashi T; Ogawa S; Tamura R; Murayama SY; Takahashi S; Tsuchimoto K
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S1-6. PubMed ID: 20586849
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in non-small cell lung carcinoma].
Lu ZQ; Li HG; Xie DR; Zhang HZ; Shen XM; Zeng YJ; Zeng H
Ai Zheng; 2005 Sep; 24(9):1132-5. PubMed ID: 16159440
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of markers and growth factors for lymphatic endothelium].
Waś H
Postepy Biochem; 2005; 51(2):209-14. PubMed ID: 16209358
[TBL] [Abstract][Full Text] [Related]
11. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins.
Tammela T; He Y; Lyytikkä J; Jeltsch M; Markkanen J; Pajusola K; Ylä-Herttuala S; Alitalo K
Circ Res; 2007 May; 100(10):1468-75. PubMed ID: 17478733
[TBL] [Abstract][Full Text] [Related]
12. The role of the VEGF-C/VEGFR-3 axis in cancer progression.
Su JL; Yen CJ; Chen PS; Chuang SE; Hong CC; Kuo IH; Chen HY; Hung MC; Kuo ML
Br J Cancer; 2007 Feb; 96(4):541-5. PubMed ID: 17164762
[TBL] [Abstract][Full Text] [Related]
13. [Lymphangiogenesis and tumor progression].
Vittet D; Feige JJ
Bull Cancer; 2007 Oct; 94(10):881-6. PubMed ID: 17964982
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
[TBL] [Abstract][Full Text] [Related]
15. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma.
Kojima H; Shijubo N; Yamada G; Ichimiya S; Abe S; Satoh M; Sato N
Cancer; 2005 Oct; 104(8):1668-77. PubMed ID: 16116610
[TBL] [Abstract][Full Text] [Related]
17. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
18. [Correlation of lymphangiogenesis to progression of colorectal cancer].
Wang TB; Huang YH; Lan P; Song XM; Wang JP
Ai Zheng; 2005 Oct; 24(10):1276-9. PubMed ID: 16219148
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
[TBL] [Abstract][Full Text] [Related]
20. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
